Clinuvel Pharmaceuticals Limited (CUV) Q4 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello everyone, thank you for joining CleanWevel's investor webinar today. I'm Stella of Monsoon Communications. In today's webinar, CleanWevel will share their results and operational highlights for the financial year ended on the 30th June 2026. I will now hand over to Malcolm Bull, Head of Australian Operations and Investor Relations to conduct the proceedings. Thank you Stella and thank you to Monsoon for hosting yet another Cliniovel results webinar. Welcome everybody on the line. There should be 130 of you very attentive to the news that we're going to provide to you. I have CFO Peter Vaughan on the line as well as our Director of Global Clinical Affairs Emily Rottenberger on the line and Managing Director Philippe Walden. Welcome executives. Thank you. Hello. Good morning. Good. The agenda today is to discuss our results for the financial year ending 30 June 2026. And we're going to have Philippe and Peter and Emily involved in various aspects of the performance and operations of the business. We also announced some other news today, the consideration of listing all of our ordinary shares on the NASDAQ. and delisting from the ASX and we'll certainly get Philippe to talk to that. We have several analysts on the line who cover Cliniville and we certainly appreciate their coverage and we welcome their participation in this webinar. They will ask some questions of our executives and then finally, time permitting, we will address a few shareholder questions that our discussion hasn't quite covered. So I should share a particular screen with you on our forward-looking statement. We will be talking about intentions and plans, and you should be aware that there's a range of risks that can materialise that affect those plans from coming to fruition. But we will try our...